Goldman Sachs Group Inc Mersana Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,959,236 shares of MRSN stock, worth $3.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,959,236
Previous 1,244,937 57.38%
Holding current value
$3.88 Million
Previous $2.5 Million 47.96%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$1.23 - $2.25 $878,587 - $1.61 Million
714,299 Added 57.38%
1,959,236 $3.7 Million
Q2 2024

Aug 13, 2024
BUY
$2.0 - $4.45 $1.14 Million - $2.55 Million
572,330 Added 85.09%
1,244,937 $2.5 Million
Q1 2024

May 15, 2024
BUY
$2.16 - $5.94 $1.14 Million - $3.13 Million
527,042 Added 362.07%
672,607 $3.01 Million
Q4 2023

Feb 13, 2024
SELL
$1.11 - $2.34 $212,551 - $448,081
-191,488 Reduced 56.81%
145,565 $337,000
Q3 2023

May 14, 2024
BUY
$1.06 - $3.91 $202,977 - $748,718
191,488 Added 131.55%
337,053 $428,000
Q3 2023

Nov 14, 2023
SELL
$1.06 - $3.91 $1.12 Million - $4.14 Million
-1,058,965 Reduced 75.86%
337,053 $428,000
Q2 2023

May 14, 2024
SELL
$3.08 - $9.55 $4.75 Million - $14.7 Million
-1,543,522 Reduced 52.51%
1,396,018 $4.59 Million
Q2 2023

Aug 14, 2023
SELL
$3.08 - $9.55 $4.75 Million - $14.7 Million
-1,543,522 Reduced 52.51%
1,396,018 $4.59 Million
Q1 2023

May 14, 2024
BUY
$4.0 - $7.02 $3.7 Million - $6.49 Million
925,044 Added 45.92%
2,939,540 $12.1 Million
Q1 2023

May 11, 2023
BUY
$4.0 - $7.02 $3.7 Million - $6.49 Million
925,044 Added 45.92%
2,939,540 $12.1 Million
Q4 2022

May 14, 2024
SELL
$5.65 - $7.86 $2.2 Million - $3.06 Million
-389,473 Reduced 16.2%
2,014,496 $11.8 Million
Q4 2022

Feb 13, 2023
SELL
$5.65 - $7.86 $2.2 Million - $3.06 Million
-389,473 Reduced 16.2%
2,014,496 $11.8 Million
Q3 2022

May 14, 2024
BUY
$4.63 - $8.0 $2.52 Million - $4.35 Million
543,622 Added 29.22%
2,403,969 $16.3 Million
Q3 2022

Nov 10, 2022
BUY
$4.63 - $8.0 $2.52 Million - $4.35 Million
543,622 Added 29.22%
2,403,969 $16.3 Million
Q2 2022

May 14, 2024
BUY
$2.84 - $5.0 $4.87 Million - $8.57 Million
1,714,782 Added 1178.02%
1,860,347 $8.6 Million
Q2 2022

Aug 15, 2022
BUY
$2.84 - $5.0 $595,249 - $1.05 Million
209,595 Added 12.7%
1,860,347 $8.6 Million
Q1 2022

May 16, 2022
BUY
$3.74 - $6.63 $1.65 Million - $2.92 Million
441,140 Added 36.47%
1,650,752 $6.59 Million
Q4 2021

Feb 14, 2022
BUY
$5.48 - $9.86 $352,051 - $633,435
64,243 Added 5.61%
1,209,612 $7.52 Million
Q3 2021

Nov 10, 2021
BUY
$8.56 - $14.47 $9.8 Million - $16.6 Million
1,145,369 New
1,145,369 $10.8 Million

Others Institutions Holding MRSN

# of Institutions
121
Shares Held
116M
Call Options Held
233K
Put Options Held
457K
View Full List

About Mersana Therapeutics, Inc.

MRSN Quotes by TradingView
  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $192M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email